Integrated Safety Analysis of Abrocitinib in 3850 Patients With Moderate-To-Severe Atopic Dermatitis: Data From More Than 9600 Patient-Years With Up to 6.5 Years of Exposure. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 9, n. 6, p. s616, 2025. DOI: 10.25251/n1p8w126. Disponível em: https://skin.dermsquared.com/skin/article/view/3820. Acesso em: 19 apr. 2026.